Univec Inc FDA Filings
Bio Remedies MD has no filings at
Univec Inc FDA Filings
Bio Remedies MD has no filings at all unless something was filed since 11/11/2022
I don't think it matters about FDA approval on the patches yes it would help but if they do the job SELL THE THINGS GET THEM ON THE MARKET IN PHARMACIES ANY WHERE They are supposedly made in a FDA approved facility and by FDA guidelines what is wrong
THEY STILL AREN'T BEING SOLD ANYWHERE NOT EVEN WITH BIO REMEDIES MD.
This page includes the latest FDA filings for Univec Inc.
FDA Filings
Device Company Device Date
PMN K993996 UNIVEC, INC. UNIVEC AUTO-DISABLE HYPODERMIC SYRINGE 2000-07-17
PMN K000747 UNIVEC, INC. UNIVEC TWO PIECE SYRINGE 2000-06-08
PMN K961877 UNIVEC, INC. PISTON SYRINGE 1996-08-07
PMN K933469 UNIVEC, INC. UNIVEC NON-REUSABLE SYRINGE 1996-04-18
PMN K951619 UNIVEC, INC. UNIVEC NONREUSABLE LOCKING SYRINGE 1995-06-06
PMN K943679 UNIVEC, INC. UNIVEC NONRESUSABLE LOCKING SYRINGE 1994-12-12
https://fda.report/Company/Univec-Inc#google_vignette
4
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Xerox Holdings Corporation Under Legal Scrutiny Faruqi & Faruqi, LLP, a prominent national securities law firm, is reaching out to investors of Xerox Holdings Corporation (NASDAQ: XRX) to inform them about an ongoing class action lawsuit. Investors are reminded of an important deadline for those wanting to assume the role of lead plaintiff in this case. The deadline for...
Continue Reading
UBS dropped a Sell rating on Dr. Reddy's Laboratories (NSE: DRRD) back in 2024, tagging the stock with a price target of INR 5,700.00. You could feel the tension shift in trading rooms as their assessment sparked fresh chatter about the firm’s US base business revenue projections that seem downright optimistic. UBS Questions Revenue Estimates: Too High or Just Right?...
Continue Reading
Assessing Market Position and Performance In the dynamic world of technology hardware, it’s crucial for investors to analyze the competition thoroughly. This article takes a closer look at Apple (NASDAQ: AAPL) and compares its financial metrics and market position against its key competitors in the industry. With this analysis, we aim to provide insights into Apple's...
Continue Reading
Back to School: Parents Brace for Sickness A recent survey shows that as children head back to the classroom, many parents anticipate facing a wave of illnesses at home. Conducted by Boiron, a leader in homeopathic remedies, this nationwide survey reveals parents' concerns about the inevitable germs that come along with the school year. Survey Insights on Parental...
Continue Reading
Scarf Systems, Inc. completed a SOC 2 Type 2 examination back in early 2023, solidifying its place as a frontrunner in data security. This wasn't just some routine check; it was a deep dive into how well Scarf protected customer data and adhered to stringent safety protocols. But here’s the kicker—traders started asking: is this enough to keep investors calm? What’s...
Continue Reading